Research programme: homosilatecan derivatives
Alternative Names: Homosilitecan derivatives - research programmeLatest Information Update: 09 Jan 2003
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Tigen Pharmaceuticals
- Class
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Feb 2000 Preclinical development for Cancer in USA (Unknown route)